DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 80.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,097 shares of the medical device company’s stock after selling 12,500 shares during the quarter. Fox Run Management L.L.C.’s holdings in DexCom were worth $241,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its holdings in shares of DexCom by 2.2% in the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after purchasing an additional 214,136 shares during the period. Jennison Associates LLC grew its position in DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after buying an additional 710,858 shares during the last quarter. Groupama Asset Managment increased its stake in DexCom by 1.1% in the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock valued at $1,912,000 after buying an additional 31,358 shares during the period. Charles Schwab Investment Management Inc. raised its position in DexCom by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock worth $219,716,000 after buying an additional 91,051 shares during the last quarter. Finally, Congress Asset Management Co. lifted its stake in shares of DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after acquiring an additional 1,332,522 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares of the company’s stock, valued at $26,183,401.02. The trade was a 8.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company’s stock.

DexCom Stock Down 3.7 %

DXCM opened at $69.47 on Friday. The firm has a market cap of $27.15 billion, a P/E ratio of 48.58, a PEG ratio of 2.30 and a beta of 1.28. The business’s fifty day simple moving average is $82.65 and its 200 day simple moving average is $77.02. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $141.99. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on DXCM shares. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Citigroup increased their target price on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Cfra Research upgraded DexCom to a “hold” rating in a research note on Friday, March 21st. Morgan Stanley increased their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Finally, Canaccord Genuity Group boosted their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.